Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9538880 | 0.86 | ATM (0.81) | LMNAPOLBATMSLC6A3HTT | |
| SCHEMBL2049574 | 0.84 | HPGD (0.59) | LMNAPOLBATMSLC6A3HPGD | |
| SCHEMBL8257597 | 0.84 | ATM (0.58) | LMNAATMSLC6A3L3MBTL1SMN1; SMN2 | |
| SCHEMBL6336570 | 0.84 | ATM (0.58) | LMNAATMSLC6A3L3MBTL1SMN1; SMN2 | |
| SCHEMBL13234917 | 0.84 | ATM (0.51) | LMNAPOLBATMSLC6A3HPGD | |
| SCHEMBL6690257 | 0.82 | ATM (0.57) | LMNAPOLBATMSLC6A3HPGD | |
| SCHEMBL22950648 | 0.82 | ATM (0.57) | LMNAPOLBATMSLC6A3HPGD | |
| SCHEMBL11097152 | 0.82 | ATM (0.57) | LMNAPOLBATMSLC6A3HPGD | |
| SCHEMBL13544537 | 0.82 | SMN1; SMN2 (0.62) | LMNAPOLBATMSLC6A3L3MBTL1 | |
| SCHEMBL8333167 | 0.81 | ATM (0.73) | POLBATMSLC6A3HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114920647-A | Novel synthesis process of intermediate side chain alcohol of medicine for treating primary hypertension | 苏州虞美景盛新药开发有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-114920647-A | Novel synthesis process of intermediate side chain alcohol of medicine for treating primary hypertension | 苏州虞美景盛新药开发有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-114920647-A | Novel synthesis process of intermediate side chain alcohol of medicine for treating primary hypertension | 苏州虞美景盛新药开发有限公司 | 2022-08-19 | — | — | CN | disclosed |
| EP-3016950-B1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9663529-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663529-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-20160152627-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160152627-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| CN-103153945-B | 1-oximino-3-phenyl-propanes | HOFFMAN-LA ROCHE LTD. (CH) | 2016-03-02 | — | — | CN | disclosed |
| EP-2593426-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-7504431-B2 | Sulfonyl amide inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-17 | — | — | US | disclosed |
| US-20050245535-A1 | Sulfonyl amide inhibitors of calcium channel function | BRISTOL- MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245535-A1 | Sulfonyl amide inhibitors of calcium channel function | CACNA1F, CACNA1A, CACNA1D | LMNA 535/4885POLB 4812/4885ATM 4315/4885 |
| US-20160152627-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | LMNA 1220/4885POLB 3485/4885ATM 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.